Clinical trials: Diabetic Nephropathy.
Worsening Chronic Heart Failure, Diabetic Nephropathy
A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution
Researchers are looking for a better way to treat people who have worsening of chronic heart failure, a long-term condition where the heart does not pump blood as well as it should, as well as to treat patients who have diabetic…
- Trial name
- NCT04881994
- Testing
- Finerenone (BAY94-8862)
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bayer
Diabetes Mellitus, Type 1, Diabetes Complications
PeRsOnalising Treatment Of Diabetic Nephropathy:
Background: Today diabetic nephropathy is a frequent, and the most lethal and costly complication of diabetes. Although treating blood pressure with agents blocking renin angiotensin system has improved outcome, the prognosis is…
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Complications, Diabetic Nephropathies
- Trial name
- PROTON (NCT03509454)
- Where
- Denmark
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Peter Rossing
Chronic Kidney Diseases
Impact of Dapagliflozin on Intestinal Microbiota Composition and on the Metabolites Derived From the Intestinal Microbiota in Non-diabetic Chronic Renal Failure Patients
Chronic kidney disease (CKD) is a common disease affecting 10-12% of the adult population and characterize with high-risk cardiovascular morbidity and mortality with progression of CKD.
- Trial name
- DAPA-GUT (NCT05965440)
- Testing
- impact of Dapagliflozin on Intestinal Microbiota on chronic renal failure patients
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Diabetic Kidney Disease
The Phase I Clinical Study to Evaluate the Pharmacokinetics of Dw1029M in Healthy Male Volunteer
1. Objective After single dose in healthy adults the capacity of the Group for DW1029M evaluate the pharmacokinetic characteristics. 2. Indication Diabetic kidney disease 3. Efficacy 1.
- Trial name
- NCT02004327
- Testing
- DW1029M300mg, DW1029M600mg, DW1029M1200mg
- Where
- South Korea
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
Contrast-induced Nephropathy
Role of Amlodipine in Reduction of CIN
The aim is to assess the benefit of low dose oral amlodipine in renal protection from contrast induced nephropathy in diabetic patients in intensive care unit
- Trial name
- NCT07291375
- Testing
- Calcium channel blocker, Hydration
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Minia University
Non-diabetic Chronic Kidney Disease, Atherosclerosis
Serum Omentin-1 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease
The aim of the study is to evaluate whether a low level of serum omentin-1 is associated with carotid atherosclerosis and mediated by inflammation.
- Trial name
- NCT01701830
- Where
- Turkey (Türkiye)
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Kocaeli Derince Education and Research Hospital
Urine VOCs From DKD and Nephrotic Syndrome Pateints
The Biosensor Using the Target Urine VOCs for Detecting DKD Diabetic Kidney Disease
Volatile organic compounds (VOCs) are easily evaporated substances produced by pathophysiologic metabolism and have been utilized in research as potential new biomarkers for differentiating various diseases, acting as the odor…
- Trial name
- VOCs in DKD (NCT07137351)
- Testing
- The Biosensor Using the Target Urine Volatile Organic Compounds
- Where
- Thailand
- Volunteers
- healthy volunteers welcome
- Sponsor
- Suranaree University of Technology
Diabetic Nephropathy
Assessment of Urinary Uromodulin and the Corresponding Gene Expression as a Biomarker of Diabetic Nephropathy
Detecting diabetes-related kidney diseases early is crucial to prevent end-stage renal disease (ESRD). Existing biomarkers' specificity and sensitivity vary, emphasizing the need for novel markers.
- Trial name
- NCT05695573
- Testing
- ACR, fasting, postprandial blood glucose ,HbA1c, creatinine, cystatin-C, BUN, Na, K , lipid profile
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Tanta University
Diabetic Nephropathy, Endothelial Dysfunction
Flavonoids in the Treatment of Endothelial Dysfunction in Children With Diabetes
Diabetes is the most common metabolic disease of childhood. Vascular disease is a leading complication of diabetes, and attempts to maintain close glycemic control do not prevent the sequelae that claim the lives and quality of…
- Trial name
- flavonoid (NCT01307917)
- Testing
- flavonoids
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Texas Tech University Health Sciences Center
Diabetic Nephropathy Type 2, Type 2 Diabetes Mellitus
Beta-2-Trace Protein in Diabetic Nephropathy
This cross-sectional study aims to evaluate serum beta-2-trace protein levels in patients with diabetic nephropathy compared with healthy controls.
- Trial name
- NCT07919795
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assiut University
Diabetes Mellitus, Type 2 Diabetes
The Hong Kong Diabetes Biobank
Asia is in the midst of an epidemic of diabetes. Epidemiological figures suggest that there are more than 110 million people affected by diabetes in China, with a significant proportion of young adults already affected.
- Conditions
- Diabetes Mellitus, Type 2 Diabetes, Type 1 Diabetes, Diabetic Nephropathies
- Trial name
- HKDB (NCT05282680)
- Testing
- prospective observational study
- Where
- Hong Kong
- Volunteers
- 48,000 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Diabetic Nephropathies
Doppler Ultrasound in Early Detection of Diabetic Nephropathy Type 2 Diabetes Mellitus.
Doppler sonography provides an easily applicable, non-invasive, and well-established method for investigating renal morphologic characteristics and measuring vascular resistance in the renal parenchyma.
- Trial name
- NCT03284996
- Testing
- Doppler ultrasonography
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assiut University
Diabetic Nephropathy
The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes
The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety…
- Trial name
- NCT00044148
- Testing
- LY333531
- Where
- 15 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Chromaderm, Inc.
Type 2 Diabetes Mellitus, Diabetic Kidney Disease
Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study.
Current study will render insight in to the role of renal hypoxia in the diabetic kidney and is able to associate its finding with measurements of renal perfusion and glomerular filtration rate.
- Conditions
- Type 2 Diabetes Mellitus, Diabetic Kidney Disease, Diabetic Nephropathy, Renal Hypoxia
- Trial name
- ROCKIES (NCT04027530)
- Testing
- Ertugliflozin 15 mg
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Diabetes
Go Fish: Omega-3 Fatty Acid Supplementation in Diabetes-Related Kidney Disease
In this application the investigators describe plans for a randomized controlled cross-over trial to determine the effects of omega-3 fatty acid supplementation on urine protein excretion in 30 adults with diabetes (NIDDM) and…
- Trial name
- NCT01092390
- Testing
- Lovaza (fish oil)
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Diabetic Kidney Disease
Diagnostic Value of Serum Cathepsin S and Chromogranin A in DKD
1. Evulate the diagnostic value of serum cathepsin S and chromogranin A for Diabetic kidney disease. 2. To correlate the levels of serum Cathepsin S and chromogranin A with HbA1c and eGFR in type 2 diabetic patients based on…
- Trial name
- NCT06069076
- Testing
- cathepsin S and chromogranin A
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Assiut University
Chronic Kidney Disease stage3
Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the newest class of orally drugs for the treatment of type 2 diabetes. These drugs decrease plasma glucose levels by inhibiting its reabsorption in the proximal tubules of the…
- Trial name
- NCT04961931
- Testing
- Empagliflozin 10 MG
- Where
- Poland
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Medical University of Lodz
Healthy Volunteers
FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects
The study will comprise primarily a single-ascending dose (SAD) escalation component.
- Trial name
- NCT03970122
- Testing
- GFB-887
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Goldfinch Bio, Inc.
Diabetic Nephropathy, Proteinuria
Effect of Turmeric on Diabetic Nephropathy
The purpose of this study is to investigate whether turmeric is effective in improvement of diabetic nephropathy and in decrease in the amount of proteinuria and cytokine levels.
- Trial name
- NCT01015937
- Testing
- Turmeric extract, Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker
- Where
- Iran
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Shaheed Faghihi Hospital
Diabetic Nephropathies
Nitric Oxide (NO) Activity and Diabetic Nephropathy
Experimental data suggest that oxidative stress and endothelial dysfunction are key players in the pathogenesis of diabetic nephropathy.
- Trial name
- NCT00136188
- Testing
- Folic Acid
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Erlangen-Nürnberg Medical School